QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical comp...

 billionaire-investor-buys-google-and-this-gold-miner-stock

John Paulson's hedge fund discloses the purchase of 9,000 shares of Alphabet.

 icahn-hedge-funds-q2-moves-centuri-stake-soars-jetblue-held-2-positions-exited

Carl Icahn's 13F shows concentrated equity book, with top 10 holdings making up 98.76%. Notable changes in non-house names ...

Core News & Articles

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulso...

 carl-c-icahn-dissolves-stake-in-bausch-health-companies-as-of-aug-14-vs-prior-stake-of-94-as-of-may-20

https://www.sec.gov/Archives/edgar/data/885590/000153949725002158/xslSCHEDULE_13D_X01/primary_doc.xml

Core News & Articles

Recent business highlights and updates:In July 2025, DURECT announced that it entered into an Agreement and Plan of Merger with...

 bausch-health-companies-q2-adj-eps-091-misses-096-estimate-sales-2530b-beat-2481b-estimate

Bausch Health Companies (NYSE:BHC) reported quarterly earnings of $0.91 per share which missed the analyst consensus estimate o...

 bausch-health-companies-raises-fy2025-sales-guidance-from-9950b-10200b-to-10000b-10250b-vs-10023b-est

Bausch Health Companies (NYSE:BHC) raises FY2025 sales outlook from $9.950 billion-$10.200 billion to $10.000 billion-$10.250 b...

 bausch-health-companies-q2-sales-2530b-beat-2481b-estimate

Bausch Health Companies (NYSE:BHC) reported quarterly sales of $2.530 billion which beat the analyst consensus estimate of $2.4...

 bausch-health-adds-late-stage-ready-alcohol-liver-disease-drug-candidate-in-63-million-durect-buyout

Bausch Health will acquire DURECT and larsucosterol, aiming for FDA approval of a first treatment for alcoholic hepatitis via P...

Core News & Articles

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy DesignationPotential to be the...

Core News & Articles

Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindam...

 bausch-health-companies-13d-filing-shows-paulson--co-inc-reports-89-stake-in-co-as-of-june-13-vs-71-as-of-may-20

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION